Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline data anticipated in H2 2024
Related news for (PULM)
- Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
- Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
- Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
- Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives